drugset / Trial / NCT05248022
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
Unknown
98 enrolled
The Central Hospital of Lishui City
Jiangxi Chest Hospital · collabJiangxi Provincial Cancer Hospital · collabThe First Affiliated Hospital of Zhengzhou University · collabZhejiang University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a prospective, multi-center, randomized, open-ended, double-arm clinical study. All eligible patients were randomly assigned to DEB-BACE combined with PD-1 inhibitor (Sindilizumab) treatment group (test group) and DEB-BACE treatment group (control group), to explore the efficacy and safety of combination therapy for stage II/III NSCLC with standard treatment failure or intolerable patients.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |